Nebulizers Market Share and Size Analysis by 2031

[Research Report] The nebulizers market was valued at US$ 815.88 million in 2023 and is expected to reach US$ 1315.57 million by 2031; it is estimated to record a CAGR of 6.2% during 2023–2031.

Market Insights and Analyst View:

The nebulizers market forecast is derived on the basis of findings from various secondary and primary research sources.

A nebulizer is a device used to deliver various medicines to help control breathing problems such as wheezing and loosen lung secretions. It converts liquid medicine into fine droplets, which are then inhaled through a mask or mouthpiece through which the medicine can enter directly into the lungs. Unlike other inhalers, nebulizers use an air compressor powered by electricity from an outlet.

Drivers and Restraints Affecting Nebulizers Market Growth

Home healthcare devices have become increasingly popular in recent years, owing to advancements in technology and miniaturization of products. This has led to a rise in adoption of home healthcare devices. Additionally, the growing number of elderly people, the high incidence of CRD, and the rising cost of healthcare services and hospital stays have resulted in a growing preference for treating patients in home care settings. Home healthcare is an affordable alternative to expensive hospital stays due to the availability of compact, portable, and patient-friendly nebulizers that are ideal for home use, coupled with technological innovations to reduce noise and improve functionality. Additionally, there is a wide range of drugs available in nebulized formulations, including long-acting beta2-agonists (LABAs), long-acting muscarinic receptor antagonists, steroids, antibiotics, and mucolytics. A few products recently launched in the market for home use are as follows:

• In January 2023, Synergy Life Science, Inc. launched Nebi, a pocket-sized nebulizer that runs on batteries and is suitable for various applications.
• In July 2021, HCmed Innovations received US Food and Drug Administration (FDA) approval for Pulmogine Vibrating Mesh Nebulizer. The device is portable and easy to use, making it a convenient solution for patients who require inhalation treatment.
• In June 2020, Respira Technologies, Inc. launched its RespiRx drug delivery device platform. This novel platform is an ultra-portable handheld vibrating mesh nebulizer (VMN) for local and systemic treatment for various target indications, including asthma and COPD.

These developments have expanded the use of nebulizers beyond acute care settings in clinics or hospitals to home care settings.

However, lack of community awareness and perception of asthma, poor access to healthcare, strained healthcare systems, a lack of diagnostic tests, including spirometry, lack of training among healthcare providers, and the lack of non-implementation of asthma guidelines are all major factors that contribute to the underdiagnosis of asthma. Asthma underdiagnosis further leads to poor clinical outcomes for patients consuming incorrect medications for treating their condition, which in turn is expected to hamper the market growth. Despite the increasing prevalence of asthma across the world, there has been a lack of acceptance of the therapies, as people are more inclined toward ayurvedic and homemade medication. The guidelines for treating asthma and chronic obstructive pulmonary disease (COPD) have changed significantly. Inhaled corticosteroids (ICSs) alone or combined with a long-acting beta2-agonist (LABA) are the first-line treatment for asthma, while long-acting muscarinic antagonists alone or in combination with LABAs are the first-line treatment for COPD. Owing to such specific combinations, there is a rise in the cost of advanced and portable nebulizers. As per an article published in September 2020 by Pubmed Central, a study was carried out to evaluate the cost-effectiveness of intravenous methylprednisolone and nebulized budesonide in treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a practical environment. The study concluded that nebulized budesonide is not a cost-effective treatment as compared to intravenous methylprednisolone for patients with AECOPD in China. Therefore, the lack of early diagnosis and the high cost of nebulizing therapy hinder the nebulizers growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Nebulizers Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The “Global nebulizers market analysis to 2031” is a specialized and in-depth study focusing on the global market dynamics to help identify the key driving factors, future trends, and lucrative opportunities in the market that would, in turn, aid in identifying major revenue pockets. The report aims to provide an overview of the market with detailed market segmentation by type, application, and end-user. The scope of the nebulizers market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

By type, the market is segmented into jet nebulizers, ultrasonic nebulizers, and mesh nebulizers. The jet nebulizers segment held the largest market share in 2022. The Mesh Nebulizers segment is projected to register the highest CAGR during 2023–2031. Jet nebulizers are affordable and easy-to-use devices that deliver medication in the form of aerosol. They are designed for one-time use, which eliminates the need for sterilization and reduces the risk of contamination. Jet nebulizers are commonly used during mechanical ventilation. The various application of these nebulizers in the treatment of CRD are propelling the jet nebulizers market size during the forecast period.

The market, by application, is segmented into COPD, asthma, cystic fibrosis, and others. The COPD segment is anticipated to hold the largest nebulizer market share in 2023. The asthma segment is projected to grow with the highest CAGR during 2023–2031. COPD is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production, and wheezing. It's typically caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer, and a variety of other conditions. According to the World Health Organization (WHO), COPD is the third leading cause of death globally. With an increase in the burden of respiratory diseases, the demand for inhalation therapies is also increasing. Additionally, the shift in preference for home care treatments fuels the utilization of hand-held nebulizers for the management of COPD and asthma.

Based on end-user, the nebulizers market is segmented into hospitals and clinics, emergency centers, and home care settings. The hospitals and clinics segment held the largest share of the market in 2023 and is expected to register the highest CAGR from 2023 to 2030 owing to the medical availability of various types of nebulizers and the growing adoption rate of these devices in hospital settings.

Regional Outlook:

North America held the largest nebulizer market share in 2023. The US held the largest share of the market in this region in 2023, followed by Canada, owing to the increasing prevalence of COPD and asthma among people in the region. According to an article published in Merck Sharp & Dohme (MSD) Manual, ~16 million people suffer from COPD, which is a leading cause of death, claiming over 150,000 lives annually in the US. Other factors propelling the growth of the nebulizers market in North America include the introduction of advanced equipment in healthcare, increasing healthcare expenditures, and the presence of leading market players, including OMRON Healthcare, BD, and GE Healthcare in the region.

Nebulizers Market Regional Insights

The regional trends and factors influencing the Nebulizers Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Nebulizers Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Nebulizers Market Market Report Scope

Market Players Density: Understanding Its Impact on Business Dynamics

The Nebulizers Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Nebulizers Market are:

1. OMRON Healthcare, Inc
2. Koninklijke Philips N.V.
3. PARI GmbH
4. Vectura Group Ltd
5. Drive DeVilbiss International

Disclaimer: The companies listed above are not ranked in any particular order.

Industry Developments and Future Opportunities:

As per company press releases, a few initiatives taken by key players operating in the global nebulizers market are listed below:

• In December 2021, Cipla Limited introduced an initiative to improve access to nebulization therapy for managing acute asthma in India's rural primary healthcare centers with its vast presence throughout the care continuum and a broad range of drug-device combinations and treatments.
• In March 2021, PARI Pharma GmbH launched its LAMIRA Nebulizer System, which has been authorized to deliver ARIKAYCE (amikacin liposome inhalation suspension) in Japan. This system uses advanced aerosol delivery systems based on eFlow Technology and features a customized medication reservoir that can hold a full dose of 8.4 ml.
• In March 2021, OMRON Healthcare, Inc. and the Asthma and Allergy Foundation of America (AAFA) collaborated to provide medical-grade nebulizers to support AAFA's advocacy and initiatives to spread awareness that aids the most vulnerable members of the asthma community.

Competitive Landscape and Key Companies:

OMRON Healthcare, Inc.; Koninklijke Philips N.V.; PARI GmbH; Vectura Group Ltd; Drive DeVilbiss International; Briggs Healthcare; GF Health Products, Inc.; GE Healthcare; Agilent Technologies, Inc.; Terumo Corporation; and Trudell Medical International are among the prominent companies profiled in nebulizers market report. These companies focus on new technologies, existing product advancements, and geographic expansions to meet the growing consumer demand worldwide.